Holen Sie sich die Stockscreener-App
26.06
1.01%
0.26
Handel nachbörslich:
26.06
Cg Oncology Inc Aktie (CGON) Neueste Nachrichten
Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going - KamloopsBCNow
Cancer Rates Are Surging in Young Adults — Here’s Where the Smart Money Is Going - Cantech Letter
CG Oncology (NASDAQ:CGON) Price Target Raised to $56.00 at Morgan Stanley - Defense World
Rhumbline Advisers Buys 5,673 Shares of CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology (NASDAQ:CGON) Trading 4.7% Higher After Analyst Upgrade - Defense World
CGON: Morgan Stanley Raises Price Target for CG Oncology | CGON Stock News - GuruFocus
CG Oncology price target raised to $56 from $52 at Morgan Stanley - TipRanks
August 15th Options Now Available For CG Oncology (CGON) - Nasdaq
Non-Muscle Invasive Bladder Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics - The Globe and Mail
Cantor Fitzgerald Predicts CG Oncology FY2026 Earnings - Defense World
California State Teachers Retirement System Buys 20,763 Shares of CG Oncology, Inc. (NASDAQ:CGON) - Defense World
Squarepoint Ops LLC Makes New Investment in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - Bluefield Daily Telegraph
CG Oncology Brings Breakthrough Bladder Cancer Treatment to Goldman Sachs Healthcare Conference - Stock Titan
Ameriprise Financial Inc. Grows Stock Holdings in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
Promising Market Position and Investment Opportunity: CG Oncology’s Creto in NMIBC Treatment - TipRanks
CG Oncology, Inc. (NASDAQ:CGON) Position Reduced by Nuveen Asset Management LLC - Defense World
BNP Paribas Financial Markets Lowers Stake in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
CG Oncology’s SWOT analysis: bladder cancer treatment stock shows promise amid competition - Investing.com
Bank of America Corp DE Has $6.01 Million Stake in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
Millennium Management LLC Invests $7.14 Million in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 1,026 Shares of CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success - MSN
Deutsche Bank AG Acquires 13,589 Shares of CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology (NASDAQ:CGON) Given New $52.00 Price Target at Morgan Stanley - Defense World
CGON Stock Rating Maintained by Morgan Stanley Despite Price Target Cut | CGON Stock News - GuruFocus
Cantor Fitzgerald Lowers Earnings Estimates for CG Oncology - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Position Boosted by Northern Trust Corp - Defense World
Q2 Earnings Forecast for CG Oncology Issued By HC Wainwright - Defense World
CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference - The Manila Times
Leading Bladder Cancer Drug Developer CG Oncology Takes Stage at Major RBC Healthcare Conference - Stock Titan
Analysts Are Bullish on These NA Stocks: American Healthcare REIT, Inc. (AHR), CG Oncology, Inc. (CGON) - The Globe and Mail
CG Oncology (NASDAQ:CGON) Shares Gap Down on Disappointing Earnings - Defense World
Decoding CG Oncology Inc (CGON): A Strategic SWOT Insight - GuruFocus
CG Oncology reports Q1 EPS (45c), consensus (37c) - TipRanks
CGON Q1 Revenue Falls Short; Advances in Bladder Cancer Therapy - GuruFocus
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates - ADVFN
CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
CG Oncology Q1 Loss Widens, Revenue Falls - marketscreener.com
CG Oncology, Inc. SEC 10-Q Report - TradingView
CG Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Here Are Reasons Why Cg Oncology Inc (NASDAQ: CGON) Is A Great Choice Now - Stocksregister
CG Oncology Jumps 25% on Positive Trial Results - Orange County Business Journal
CG Oncology (NASDAQ:CGON) Earns Overweight Rating from Analysts at JPMorgan Chase & Co. - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Recommendation of “Buy” by Analysts - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Shares Purchased by Invesco Ltd. - Defense World
CG Oncology initiated with an Overweight at JPMorgan - TipRanks
CGON Stock: JP Morgan Initiates Coverage with Overweight Rating - GuruFocus
JPMorgan Initiates Coverage on CG Oncology With Overweight Rating, $41 Price Target - marketscreener.com
CGON: JPMorgan Starts Coverage with Overweight Rating and $41 Ta - GuruFocus
CG Oncology (NASDAQ:CGON) Reaches New 1-Year Low After Insider Selling - Defense World
CGON: JPMorgan Starts Coverage with Overweight Rating and $41 Target | CGON Stock News - GuruFocus
Why CG Oncology, Inc. (CGON) Surged on Monday - MSN
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
1.06%
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):